Amended Current Report Filing (8-k/a)
08 July 2021 - 6:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K/A
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 28, 2021
Todos
Medical Ltd.
(Exact
name of registrant as specified in its charter)
Israel
|
000-56026
|
n/a
|
(State
or other jurisdiction
|
(Commission
|
IRS
Employer
|
of
incorporation or organization)
|
File
Number)
|
Identification
No.)
|
121
Derech Menachem Begin, 30th Floor
Tel
Aviv, 6701203 Israel
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: 972 (52) 642-0126
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ]
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth
company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 – Other events.
Explanatory
Note
This
Amendment No. 2 on Form 8-K/A amends (i) the Current Report on Form 8-K of Todos Medical Ltd. dated June 28, 2021, and
filed with the Securities and Exchange Commission on June 28, 2021 (the “Original Filing”) and (ii) Amendment No. 1 to the
Original Filing, dated June 29, 2021, and filed with the Securities and Exchange Commission on June 29, 2021. This Amendment No. 2
is being provided solely to correct a clerical error with respect to the number of ordinary shares issued and outstanding as of the Record
Date for our shareholders’ meeting to be held on July 26, 2021.
The
number of ordinary shares issued and outstanding as of the Record Date is 607,760,492.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
By:
|
/s/
Gerald Commissiong
|
|
Name:
|
Gerald
Commissiong
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
Date:
July 7, 2021
|
|
|
Todos Med (CE) (USOTC:TOMDF)
Historical Stock Chart
From Apr 2024 to May 2024
Todos Med (CE) (USOTC:TOMDF)
Historical Stock Chart
From May 2023 to May 2024